Immediate Implant Placement With Subepithelial Connective Tissue Grafting and Probiotics

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-45
SponsorKafrelsheikh University

About this trial

The present study aims to evaluate and compare the clinical, radiographic, and biological peri-implant tissue outcomes of platelet-rich fibrin versus probiotics as adjuncts to immediate implant placement combined with subepithelial connective tissue grafting in adults requiring single immediate implant placement.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults aged 20 to 45 years.

Systemically healthy patients eligible for implant surgery.

Patients requiring extraction of a single non-restorable tooth indicated for immediate implant placement.

Implant sites located in the maxillary esthetic or para-esthetic zone.

Disqualifiers

Medically compromised patients or patients with systemic conditions that may contraindicate implant surgery or interfere with healing.

Smokers.

Pregnant or lactating women.

Patients with uncontrolled periodontal disease or poor oral hygiene.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Platelet-Rich Fibrin

    Procedure/Surgery

    platelet-rich fibrin will be prepared immediately before application using freshly drawn autologous venous blood and a standardized centrifugation protocol selected according to the equipment available in the study setting. The prepared PRF will be used as an adjunct to the immediate implant and subepithelial connective tissue grafting procedure according to the finalized protocol, either locally around the peri-implant site and/or in intimate relation to the grafted soft tissue to enhance healing and tissue maturation.

  • Probiotics

    Procedure/Surgery

    Probiotics probiotics will be administered as an adjunct to the immediate implant and subepithelial connective tissue grafting The mode of delivery, dose, and duration will be standardized for all patients allocated to this group.

Treatment groups

22 Participants
are divided into 2 treatment groups
Group A: platelet-rich fibrin groupExperimental treatment 1 intervention
Group B: probiotics groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

evaluation of matrix metalloproteinase-8 (MMP-8) levels

Biological assessment will be performed by collecting peri-implant sulcular fluid samples for evaluation of matrix metalloproteinase-8 (MMP-8) levels. After gentle removal of supragingival plaque, the peri-implant site will be isolated with cotton rolls and dried with mild air flow. Sterile PerioPaper strips will be inserted carefully into the peri-implant sulcus until slight resistance is encountered and left in place for 30 seconds. Any strip contaminated with blood or saliva will be discarded. The collected samples will be transferred to sterile Eppendorf tubes and stored until analysis. Quantitative assessment of MMP-8 will be carried out using a human MMP-8 ELISA kit according to the manufacturer's protocol.

Time frame
12-months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: